Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Net Cash Flow (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Net Cash Flow for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 107.96% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.9 million through Dec 2025, up 88.72% year-over-year, with the annual reading at -$3.9 million for FY2025, 88.72% up from the prior year.
  • Net Cash Flow for Q4 2025 was $1.2 million at Caribou Biosciences, up from -$14.1 million in the prior quarter.
  • The five-year high for Net Cash Flow was $305.8 million in Q3 2021, with the low at -$194.9 million in Q4 2021.
  • Average Net Cash Flow over 5 years is -$177350.0, with a median of -$8.7 million recorded in 2024.
  • Peak annual rise in Net Cash Flow hit 3662.69% in 2021, while the deepest fall reached 2167.74% in 2021.
  • Over 5 years, Net Cash Flow stood at -$194.9 million in 2021, then surged by 87.82% to -$23.7 million in 2022, then tumbled by 122.75% to -$52.9 million in 2023, then soared by 70.36% to -$15.7 million in 2024, then soared by 107.96% to $1.2 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $1.2 million, -$14.1 million, and -$4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.